Hemogenyx Raises £2.5M to Advance CAR-T Therapy for Acute Myeloid Leukemia
核心洞察
Hemogenyx Pharmaceuticals (搜索) secured £2.5 million in funding to continue phase I clinical trials of its CAR-T therapy HG-CT-1 for relapsed or refractory acute myeloid leukemia.
The company received positive recommendation from the independent Data Safety Monitoring Board to continue dose escalation in adults and FDA clearance for pediatric trials in patients aged 12-18 years.
The funding follows strategic cost reduction measures including outsourcing HG-CT-1 manufacturing to specialized third-party providers.
Hemogenyx Pharmaceuticals (搜索) has raised £2.5 million through a direct subscription by private investors to support the continuation of its phase I clinical trials for CAR-T therapy HG-CT-1 targeting relapsed or refractory acute myeloid leukemia in both adult and pediatric patients.
The London-listed biotechnology company issued 313,333 new shares at £7.50 each, with investors also receiving three-year warrants exercisable at £9 per share. The net proceeds are primarily earmarked to fund ongoing phase I trials of HG-CT-1, marking a significant milestone in the company's clinical development program.
Clinical Progress and Regulatory Milestones
The fundraising follows two critical regulatory developments that underscore the therapy's potential. The independent Data Safety Monitoring Board issued a positive recommendation to continue dose escalation in adults, while the US Food & Drug Administration granted clearance to begin a phase I trial in patients aged 12 to 18 years.
CEO Vladislav Sandler emphasized the company's focus on clinical execution: "Following the positive recommendation from the DSMB to continue the adult trial at the next dose level and the receipt of FDA clearance to initiate the paediatric study, the Company remains focused on executing its clinical programme."
Strategic Operational Changes
In parallel with the clinical advancement, Hemogenyx has implemented cost reduction measures to optimize operational efficiency. The company has outsourced the manufacture of HG-CT-1 to a specialized third-party provider, representing a strategic shift in its manufacturing approach.
This operational restructuring aligns with the company's broader strategy to focus resources on clinical development while leveraging external expertise for manufacturing capabilities. The move is expected to reduce operating costs while maintaining quality standards for the investigational therapy.
Market Performance and Investor Confidence
Hemogenyx shares rose 12% to 1,021.00 pence following the funding announcement, reflecting investor confidence in the company's clinical progress. The stock has demonstrated significant volatility over the past 12 months, trading within a range of 124.00p to 1,800.00p.
The successful fundraising at £7.50 per share, with additional warrant coverage, demonstrates continued investor appetite for the company's CAR-T platform despite the challenging biotech funding environment.